<DOC>
	<DOCNO>NCT01168752</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose Debio 0932 administer orally , every-other-day daily first 30 day , patient solid tumour lymphoma .</brief_summary>
	<brief_title>Study Debio 0932 Patients With Advanced Solid Tumours Lymphoma</brief_title>
	<detailed_description>This open-label , non-randomised , dose-escalation phase I , pharmacokinetic pharmacodynamic study patient advance and/or refractory malignancy ( solid tumour lymphoma ) , determine maximum tolerate dos ( MTD ) Debio 0932 administer orally every-other-day ( schedule A ) every day ( schedule B ) ass safety profile , pharmakokinetic , antitumor activity pharmacodynamic biomarkers . Increments use dose escalation determine accord maximum grade treatment-related adverse event observe first 30-day treatment period schedule previous precede dose level Once reach recommend dose ( RD ) schedule , 40 additional patient enrol treated RD retain schedule , part expansion phase .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Histologically confirm diagnosis advance solid tumour lymphoma , except primitive hepatocarcinoma radiological diagnosis permit ; Advanced metastatic disease refractory standard curative palliative therapy contraindication refuse standard therapy , Measurable and/or evaluable disease , Age ≥ 18 year , ECOG performance ≤ 1 Life expectancy ≥ 3 month , If female , neither pregnant lactating , Negative pregnancy test female screen , preferably do within 1 week Day 1 treatment ( applicable patient bilateral oophorectomy and/or hysterectomy ) , Agreeing use appropriate medically approve contraception ( physical barrier contraception recommend ) study entry 6 month last day treatment patient , Absolute neutrophil count ≥ 1,500/µL ; platelet ≥ 100,000/µL ; calculate creatinine clearance ≥ 60mL/min ( calculate accord formula Cockroft Gault ) ; total bilirubin ≤ 1.5x ULN ; AST/ALT ≤ 2.5x ULN . In patient document liver metastasis , AST/ALT may ≤ 3.5x ULN ; prothrombin time ≤1.5x ULN , kalemia , magnesemia phosphatemia &gt; LLN ( Lower Limit Normal ) Able render inform consent follow protocol requirement , Able swallow capsule , Able comply schedule plan , laboratory test , study procedure . Received investigational agent systemic anticancer agent within 14 day Day 1 treatment , 28 day agent unknown elimination halflives , know elimination halflives great 50 hour ; 6 week Mitomycine C nitrosourea agent , Unresolved toxicity previous treatment previous investigational agent , Patients history prior radiation potentially include heart field ( e.g . mantle ) , Cardiac exclusion criterion : History significant coronary artery disease congestive heart failure meet NYHA class III IV , within 12 month ( see Appendix D ) , Significant cardiovascular dysfunction : pulmonary hypertension , right ventricular systolic dysfunction , aortic stenosis , mitral insufficiency &gt; grade 2 and/or Left Ventricular Ejection fraction &lt; 45 % &lt; 55 % prior exposure anthracyclines , base MUGA echocardiography , Uncontrolled hypertension ( Systolic &gt; 150 diastolic &gt; 100 ) , Permanent uncontrolled cardiac rhythm disorder clinical relevant abnormality 12lead ECG/Holter , WPW ( WolffParkinsonWhite ) syndrome , QRS &gt; 120 msec , PR &gt; 220 msec , heart rate &lt; 50 bpm , Q wave , ST deviation , leave bundle branch block , atrial fibrillation , flutter , tachysystoly . Prolonged QTc interval &gt; 450 msec men &gt; 470 msec woman use Fridericia formula , Congenital long QT syndrome , Use medication associate know QTc interval prolongation ( nonexhaustive list provide separately ) Known infection human immunodeficiency virus ( HIV ) , hepatitis B hepatitis C , Patients uncontrolled brain metastasis , Gastrointestinal diseases disorder could affect drug absorption diarrhoea , major abdominal surgery , significant bowel obstruction and/or gastrointestinal disease could alter assessment safety , include follow : Irritable bowel syndrome Ulcerative colitis Crohn disease Haemorrhagic coloproctitis Concurrent participation anticancer therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Cancer</keyword>
	<keyword>solid tumour</keyword>
	<keyword>lymphoma</keyword>
	<keyword>dose-escalation</keyword>
	<keyword>Hsp90 inhibitor</keyword>
</DOC>